{"disease":{"id":"kras-activating-mutation","name":"kras activating mutation"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04620330","title":"A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":90,"lead_sponsor_name":"Verastem, Inc.","has_results":false},{"nct_id":"NCT05375994","title":"Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":85,"lead_sponsor_name":"Verastem, Inc.","has_results":false},{"nct_id":"NCT05669482","title":"Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":40,"lead_sponsor_name":"Verastem, Inc.","has_results":false},{"nct_id":"NCT04470674","title":"Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (≥ 50%) NSCLC Patients","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Shirish M Gadgeel","has_results":false},{"nct_id":"NCT04566393","title":"Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies","phase":"","overall_status":"AVAILABLE","enrollment_count":null,"lead_sponsor_name":"xCures","has_results":false}],"total":5},"guidelines":[],"source":"Drug Landscape verified database"}